Niraparib
Generic Details
Generic Name
Niraparib
Other Names
Drug Class
- PARP inhibitor
Chemical Formula
C19H20N4O2
Molecular Weight
320.39 g/mol
Mechanism of Action
- Inhibits poly (ADP-ribose) polymerase (PARP) enzymes, which play a role in DNA repair processes, leading to cancer cell death.
Indications
- Ovarian cancer
- Breast cancer
- Fallopian tube cancer
- Primary peritoneal cancer
Common Dosage Forms
- Capsules
Typical Dosage
- 300 mg once daily
Pediatric Dosage
Geriatric Dosage
Side Effects
- Nausea
- Fatigue
- Thrombocytopenia
- Anemia
- Constipation
- Vomiting
- Diarrhea
- Musculoskeletal pain
Contraindications
- Hypersensitivity to niraparib
Pregnancy Category
- D
Lactation Safety
- May not be safe during breastfeeding
Drug Interactions
- Strong CYP3A4 inhibitors/inducers
- P-gp inhibitors/inducers
Overdose Symptoms
- Increased risk of myelosuppression and gastrointestinal toxicity
Antidote for Overdose
- No specific antidote, manage symptoms and provide supportive care
Storage Conditions
- Store at room temperature (20-25°C)
- Protect from light and moisture
Pharmacokinetics
- Absorption: Well absorbed orally
- Distribution: Extensively distributed in the body
- Metabolism: Primarily hepatic via carboxylesterase 2 and CYP3A4
- Excretion: Mainly through feces
Precautions
- Monitor blood counts regularly during treatment
- Use with caution in patients with renal impairment
Warnings
- Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) have been reported with niraparib
Others
- It is important to inform the healthcare provider about all medications, supplements, and herbal products being taken before starting niraparib.